Download Files:
Products Details
Product Description
– JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis[1].
Web ID
– HY-156034
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C19H22N4O4S
References
– [1]Povero D, et, al. Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. J Pharmacol Exp Ther. 2023 Aug;386(2):242-258.
CAS Number
– 2238819-65-1
Molecular Weight
– 402.47
SMILES
– O=C(NS(=O)(C1=C2OCCCN2N=C1)=O)NC3=C4CCCC4=CC5=C3CCC5
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– NOD-like Receptor (NLR)
Isoform
– NLRP3
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
